Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

Regeneron and Sanofi said an FDA green light would make Dupixent the first targeted medicine in the U.S. for bullous pemphigoid, a debilitating and relapsing skin disease with underlying type 2 ...

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...

Bullous Pemphigoid Market Outlook 2025-2035: The 7 major Bullous Pemphigoid market reached a value of USD 287.1 Million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 1,618.1 ...

1 Department of Oral Mucosa, Qingdao Stomatological Hospital Affiliated to Qingdao University, Qingdao, China 2 Department of Oral Medicine, Peking University School and Hospital of Stomatology, ...

Background: The association between psoriasis vulgaris and bullous pemphigoid (BP) remains largely unknown. Objectives: To investigate whether there is a causal effect between psoriasis vulgaris and ...